Monomethyl fumarate structure
|
Common Name | Monomethyl fumarate | ||
---|---|---|---|---|
CAS Number | 2756-87-8 | Molecular Weight | 130.099 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 250.0±23.0 °C at 760 mmHg | |
Molecular Formula | C5H6O4 | Melting Point | 144-145ºC | |
MSDS | Chinese USA | Flash Point | 108.9±16.1 °C | |
Symbol |
GHS05 |
Signal Word | Danger |
Use of Monomethyl fumarateMonomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3]. |
Name | Fumaric Acid Monomethyl Ester |
---|---|
Synonym | More Synonyms |
Description | Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Monomethyl fumarate completely inhibits forskolin induced cAMP synthesis with an IC50 of 70 nM. Monomethyl fumarate induces a dose-dependent Ca2+ signal in GPR109A transfected cells with an EC50 of 9.4 μM[1]. Monomethyl fumarate (25 μM; 24 hours) attenuates 7β-OHC-induced cytotoxicity: cell growth inhibition; decreased cell viability; mitochondrial dysfunction; and cell death induction[3]. |
In Vivo | A single dose of Monomethyl fumarate (50-100 mg/kg; IP) before light exposure prevents these morphologic changes (bright light exposure induced photoreceptor death) in a dose-dependent manner[2]. Monomethyl fumarate (100 mg/kg) reduces retinal inflammation and oxidative stress. Monomethyl fumarate significantly suppresses light-induced retinopathy (LIR) upregulated genes in the NFkB pathway including: Nlrp3, Casp1, Il-1β, and Tnf-α[2]. Animal Model: Albino BALB/c mice (male, 6 weeks old)[2] Dosage: 50, 65, 75, 100 mg/kg Administration: IP Result: Prevented these morphologic changes (bright light exposure induced photoreceptor death) in a dose-dependent manner. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 250.0±23.0 °C at 760 mmHg |
Melting Point | 144-145ºC |
Molecular Formula | C5H6O4 |
Molecular Weight | 130.099 |
Flash Point | 108.9±16.1 °C |
Exact Mass | 130.026611 |
PSA | 63.60000 |
LogP | -0.24 |
Vapour Pressure | 0.0±1.1 mmHg at 25°C |
Index of Refraction | 1.469 |
Symbol |
GHS05 |
---|---|
Signal Word | Danger |
Hazard Statements | H318 |
Precautionary Statements | P280-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi:Irritant; |
Risk Phrases | R41 |
Safety Phrases | S26-S39 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
HS Code | 2918990090 |
Precursor 10 | |
---|---|
DownStream 5 | |
HS Code | 2918990090 |
---|---|
Summary | 2918990090. other carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.
J. Neuropathol. Exp. Neurol. 74 , 1093-118, (2015) Despite effective viral suppression through combined antiretroviral therapy (cART), approximately half of HIV-positive individuals have HIV-associated neurocognitive disorders (HAND). Studies of antir... |
|
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A).
Bioorg. Med. Chem. Lett. 21 , 2736-9, (2011) Nicotinic acid (niacin) has been used for decades as an antidyslipidemic drug in man. Its main target is the hydroxy-carboxylic acid receptor HCA2 (GPR109A), a G protein-coupled receptor. Other acids ... |
|
Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway.
Br. J. Pharmacol. 172 , 3929-43, (2015) Dimethyl fumarate (DMF) is a newly approved drug for the treatment of relapsing forms of multiple sclerosis and relapsing-remitting multiple sclerosis. Here, we investigated the effects of DMF and its... |
MFCD00063174 |
(2E)-4-Methoxy-4-oxobut-2-enoic acid |
2-Butenedioic acid, monomethyl ester, (2E)- |
EINECS 220-412-6 |
(2E)-4-Methoxy-4-oxo-2-butenoic acid |
Methyl Hydrogen Fumarate |
2-Butenedioic acid, monomethyl ester |
Monomethyl Fumarate |
4-Methoxy-4-oxobut-2-enoic acid |
Fumaric acid, monomethyl ester |